BDBM361982 US10221182, Compound E1-1.5::US10221182, Compound E2-1.5

SMILES FC(F)(F)c1ccc(CCN2CCC(Nc3ncnc4[nH]ncc34)C(F)(F)C2)cc1

InChI Key InChIKey=JZWSSGCJYKYCCT-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 361982   

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 32.9nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 32.9nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 32.9nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 37.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 37.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 37.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 7.60E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 9.80E+3nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 1.52E+4nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361982(US10221182, Compound E2-1.5 | US10221182, Compound...)
Affinity DataIC50: 3.41E+4nMAssay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
Go to US Patent